1 / 15

DAIICHI SANKYO

DAIICHI SANKYO. US Corporate Headquarters Parsippany, NJ November 3, 2006. Rutgers Business School Site Visit Prep Session Ryan Field Iffat Ali. Daiichi Sankyo Co., Ltd. Daiichi Pharmaceutical Co. founded 1915 Sankyo established 1899 Merged September 2005

sai
Download Presentation

DAIICHI SANKYO

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DAIICHI SANKYO US Corporate Headquarters Parsippany, NJ November 3, 2006 Rutgers Business School Site Visit Prep Session Ryan Field Iffat Ali

  2. Daiichi Sankyo Co., Ltd. • Daiichi Pharmaceutical Co. founded 1915 • Sankyo established 1899 • Merged September 2005 • Second largest Japanese pharma company • $7.9B (North America: 12.5%)* • Focus on pharmaceutical products Takashi Shoda, President, CEO, and Representative Director of Board of Directors *Note: Financial information is from FY ending March 2006

  3. Daiichi Sankyo’s Legacy Washington DC cherry trees donated in 1912 by first president of Sankyo, Jokichi Takamine

  4. Daiichi Sankyo, Inc. • US integrated operations: • Established April 2006 • Headquarters: • 2 Hilton Court Parsippany, NJ 07054 (973) 359-2600 • Website: • www.daiichisankyo-us.com

  5. Integration of US Subsidiaries • Three subsidiaries: • Sankyo Pharma Inc. • Daiichi Pharmaceutical Corp. • Daiichi Medical Research Joe Pieroni, president of Daiichi Sankyo, US

  6. Integration of US Subsidiaries • Combined sales force • Primary focus on cardiovascular disease • Additional R&D areas: • Glucose metabolic disorders • Infectious diseases • Cancer • Immunology • Bone and joint diseases

  7. Daiichi SankyoPharma Development • Product development • Clinical development • Translational medicine • Clinical pharmacology • Regulatory affairs • Risk management • Informatics and knowledge management • Biostatistics and data operations • Development research

  8. Daiichi SankyoResearch Institute (DSRI) • Building relationships • Academic institutions • Biotechnology firms • Research alliances • Manage partnership with venture funds

  9. Alliances with Biotechnology Firms • KAI Pharmaceuticals • MorphoSys • Exelixis

  10. US Products • WelChol • Cholesterol lowering • 15-18% reduction in LDL • Non-systemic • Not absorbed into bloodstream • Binds to bile acids in the intestines, carries out of body • Can be used in combination with a statin drug

  11. US Products • Benicar • Hypertension (high blood pressure) • Angiotensin receptor blocker (ARB) • Benicar HCT • Benicar + thiazide diuretic (HCTZ) • HCTZ works by increasing water excretion • Complimentary effect on reducing HBP • Not intended for initial treatment

  12. US Products • Floxin Otic • Eardrop antibiotic • Children / Adults • Otitis Media / Otitis Externa • Middle / Outer ear infection (swimmer’s ear) • Two packages • Bottles • Single use vials

  13. US Products • Evoxac • Sjögren's syndrome • Dry mouth symptoms • Stimulates natural flow of saliva

  14. Product Pipeline

  15. Topics for Tomorrow Program begins at 1:00PM • Overview of Daiichi Sankyo and the Management Development Program • New Product Planning • Supply Chain and Sales Operations • Product Management/Market Research • Facility Tour • Managed Care

More Related